The cumulative probability of cervical cancer was lower in the SGLT2 inhibitor group than in the control group after both 2:1 sex and age matching (P = 0.0020) and PSM (P = 0.0109) (Figure 2). Here, SLC5A2 is linked to cervical carcinoma.